Three biopharmaceutical companies launched US initial public offerings in January, kicking off 2017 with more confidence than drug developers showed in 2016 when there were no biopharma IPOs during the first month of the year.
With the AnaptysBio Inc., Jounce Therapeutics Inc. and ObsEva SA offerings in January, 2017 is a bit ahead of 2016, which had 30 biopharma IPOs – an...